Company: CORT
Filing Date: 2025-05-05
Form Type: 10-Q
Source: 0001628280-25-022173
Chunk: 189

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-05-05
Form: 10-Q
Item: Part I, Item 4
Chunk 189
---
 intention of buying it back later at a lower price, thereby profiting from any decline in the price of the stock between the time it is sold and the time it is repurchased. To support their efforts, short sellers often publish, or arrange for others to publish, negative opinions regarding the relevant issuer and its business prospects. These publications are often made to appear as if they were objective journalism or unbiased “research reports” of the type distributed by credible Wall Street firms and independent research analysts. Short seller publications are not regulated by any governmental, self-regulatory organization or other authority in the United States and the opinions they express are often based on distortions, omissions or fabrications. Short attacks supported by such publications have, in the past, led to selling of our stock and at least temporary reductions in its price. Companies that are subject to unfavorable allegations, even if untrue, may have to expend a significant amount of resources to investigate such allegations and/or defend themselves, including 

34

shareholder suits against the company that may be prompted by such allegations. We have been, and may in the future be, the subject of shareholder suits prompted by allegations made by short sellers.

General Risk Factors

We face unprecedented political, legal, governmental, regulatory and economic uncertainty and risks that may adversely affect our business.

Actions taken by the presidential administration in the United States have caused great uncertainty. The administration’s policies and their implementation, including with respect to tariffs and trade, funding for the FDA and other key agencies, and funding for scientific research both within the government and at universities, have been unpredictable and generally adverse to our clinical and commercial efforts. The administration may adopt new policies or take new actions, without notice, that damage our commercial interests or make it more difficult or costly to develop our product candidates. Significant cuts or disruptions to the staffing of government agencies or spending may delay review of our NDA for relacorilant as a treatment for patients with hypercortisolism and may hamper our ability to advance our other clinical programs. Similarly, the research programs of our academic collaborators may be defunded.

The imposition of tariffs on materials we or our vendors use to conduct experiments or to make our Products or product candidates have increased our costs and may increase them further. The United States’ tariff regime and the tariff regime of its trading partners are in constant flux. Although we monitor the situation closely, the tariffs that may affect our business are difficult to predict. There can be no assurance that we can anticipate new trade measures or mitigate their impacts, which could